Medscape is available in 5 Language Editions – Choose your Edition here.


Dysthymic Disorder

  • Author: Jerry L Halverson, MD; Chief Editor: David Bienenfeld, MD  more...
Updated: Nov 09, 2015


In the American Psychiatric Association’s Diagnostic and Statistical Manual, Fifth Edition, (DSM-5), persistent depressive disorder (dysthymia) represents a consolidation of DSM-IV defined chronic major depressive disorder and dysthymic disorder.[1] Persistent depressive disorder is a depressive mood disorder characterized by a chronic course and an early and inisidious onset (i.e., in childhood, adolescence, or early adulthood). Early onset (i.e., before age 21) is associated with higher risk for comorbid personality disorders and substance use disorders.

Although dysthymia was traditionally considered less severe than major depression, the consequences of dysthymia are increasingly recognized as grave; they include severe functional impairment, increased morbidity from physical disease, and increased risk of suicide. (See Prognosis.)

Anxious versus anergic dysthymia

Niculescu and Akisal proposed that dysthymia be divided into 2 subtypes: anxious dysthymia and anergic dysthymia. They described the subset of patients with anxious dysthymia as having pronounced symptoms of low self-esteem, undirected restlessness, and interpersonal rejection sensitivity. They also characterized these patients as help-seeking and more likely to make lower-lethality suicide attempts and to have a better response to selective serotonin reuptake inhibitors (SSRIs). Substances of choice for these patients include benzodiazepines, alcohol, marijuana, opiates, and possibly food. (See Treatment and Medication.)[2]

This group is compared with persons who have anergic dysthymia, characterized by low energy, hypersomnia, and anhedonia. Patients with anergic dysthymia, the authors suggest, may have a better response to treatment with agents that increase norepinephrine or dopamine. (See Treatment and Medication.)

Of note, an estimated 75% of people with dysthymia meet criteria for at least 1 major depressive episode, referred to as double depression.[7] Those with dysthymia who have depressive episodes tend to have longer periods of depression and spend less time fully recovered.[8] In a 10-year follow-up study of people with dysthymia, 75% experienced some (at least 2mo) period of recovery from major depression; the mean time to recovery was 52 months from study entry. In this study, most (70%) of those who recovered experienced a relapse into another episode of depression, most commonly in the 3 years following recovery.[9]

Diagnostic criteria (DSM-5)

The specific DSM-5 criteria for persistent depressive disorder (dysthymia) are as follows:[1]

Depressed mood for most of the day, for more days than not, as indicated by either subjective account or observation by others, for at least 2 years. In children and adolescents, mood may be irritable and duration must be at least 1 year.

Presence, while depressed, of two (or more) of the following:

  • Poor appetite or overeating
  • Insomnia or hypersomnia
  • Low energy or fatigue
  • Low self-esteem
  • Poor concentration and/or difficulty making decisions
  • Feelings of hopelessness

During the 2-year period (1 year for children and adolescents) of the disturbance, the individual has never been without symptoms in Criteria A and B for more than 2 months at a time.

Criteria for major depressive disorder may be continuously present for 2 years.

There has never been a manic episode or a hypomanic episode, and criteria have never been met for cyclothymic disorder.

The disturbance is not better explained by a persistent schizoaffective disorder, schizophrenia, delusional disorder, or other specified or unspecified schizophrenia spectrum and other psychotic disorders.

The symptoms are not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition (e.g., hypothyroidism).

The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.

As with other depressive disorders, persistent depressive disorder (dysthymia) can be given further specifiers:

  • With anxious distress
  • With mixed features
  • With melancholic features
  • With atypical features
  • With mood-congruent psychotic features
  • With mood-incongruent psychotic features
  • With peripartum onset


The cause of dysthymia, although not clear, is likely multifactorial. A biopsychosocial formulation considering the interplay of family history and other genetic factors, medical problems, psychological make-up and coping strategies, and social stressors, is helpful when considering the cause of dysthymia. Some examples of common contributing factors include the following:

  • Genetic predisposition
  • Biological factors - Such as alterations in neurotransmitters, endocrine, or inflammatory mediators
  • Chronic stress - Particularly with feelings of hopelessness and/or helplessness
  • Chronic medical illness
  • Psychosocial factors - Such as social isolation, losses
  • Ruminative coping strategies - These, as opposed to problem solving or cognitive restructuring strategies, are common among people with dysthymia and may predispose to or sustain dysthymia [13]
  • Antisocial, borderline, dependent, depressive, histrionic, or schizotypal personality traits - People diagnosed with these are at an increased risk for developing dysthymic disorder [14, 15]

Electroencephalogram (EEG) and polysomnogram data demonstrate that about 25% of people who have dysthymia have sleep changes similar to those of persons who have major depression, including shortened rapid eye movement (REM) latency, increased REM density, and poor sleep continuity.

Physiology of dysthymia

The involvement of serotonin and noradrenergic systems in dysthymia is suggested by the disease’s positive clinical responses to serotonergic and noradrenergic medications, such as SSRIs, serotonin/norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants.

Abnormalities in neuroendocrine systems, especially thyroid and hypothalamo-pituitary-adrenocortical (HPA) systems, have been linked to depressive disorders in general, although the HPA axis has not been adequately studied in dysthymic disorder.

Cytokines and inflammation have also been implicated in major depression; however, a link to dysthymia has not been clearly established.




Best estimates are that the lifetime risk of significant depression exceeds 25%, with a point prevalence of about 5%. The lifetime community prevalence of dysthymia is 6%. Dysthymia affects an estimated 36% of patients in outpatient mental health treatment.


Minimal research has been performed to define differences in frequency and symptoms between races. One study, the National Health and Nutrition Examination Survey III (NHANES III), found that dysthymia is more common among African Americans and Mexican Americans than among Caucasians.[16]

For major depressive disorders, females outnumber males, with a female-to-male ratio of 2:1 during their childbearing years. Before puberty and after menopause, the 2 sexes appear to be affected about equally. In elderly people, dysthymia is relatively more frequent in females, but dysthymia adversely affects survival in males more than in females.





Dysthymia is by definition chronic. Periods of depression or euthymia may occur during the course of the illness. A systematic review of epidemiologic studies found that 46-71% of persons with dysthymia reported remission at follow-up points ranging from 1-6 years.

Comorbidities, such as anxiety disorders and depressive personality disorder, are associated with lower recovery rates.[18, 10, 19, 12] Chronic stress is associated with more severe symptoms and a lower likelihood of recovery.[19]

With adequate treatment, substantial, prolonged improvement can be expected in most patients. Emphasis is increasing on the importance of striving for remission, rather than response, when treating depressive disorders, as is the strategy with other mood disorders.[20, 21]

Morbidity and mortality

Patients should be closely monitored for the emergence of major depression or bipolar disorder. Review of longitudinal studies showed that 76% of dysthymic children developed major depression and that 13% developed bipolar disorder over follow-up periods of 3-12 years.

Patients with dysthymia have a higher risk of employment problems, including decreased productivity and increased unemployment.[22] A study found that at 6 months, 14% of patients with dysthymia were newly unemployed, compared with 2% new unemployment in the control group and 3% new unemployment in a group with rheumatoid arthritis.[23]

Additional concerns in dysthymia include the following:

  • Increased mortality and morbidity from unrelated physical illnesses - Dysthymia is associated with poorer self-rated health status [24]
  • Suicide, attempted or completed - Dysthymia significantly increases risk of suicide [25, 26]

Patient Education

If possible, family members and other significant individuals should be helped to understand depression, to view the patient's complaints as symptoms of an illness, and to be sensitive to signs of major depression, with its risk of suicide. For example, an increase in irritability often heralds the progression from dysthymia to depression and may be apparent to people close to the patient before the patient is aware of the change.

The following Web sites contain additional patient information:

For patient education information, see the Depression Center, as well as Depression.

Contributor Information and Disclosures

Jerry L Halverson, MD Medical Director of Adult Services, Rogers Memorial Hospital; Voluntary Clinical Assistant Professor, Department of Psychiatry, University of Wisconsin School of Medicine and Public Health; Clinical Assistant Professor of Psychiatry, Department of Psychiatry and Behavioral Sciences, Medical College of Wisconsin

Jerry L Halverson, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, American College of Psychiatrists

Disclosure: Nothing to disclose.

Chief Editor

David Bienenfeld, MD Professor, Departments of Psychiatry and Geriatric Medicine, Wright State University, Boonshoft School of Medicine

David Bienenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, Association for Academic Psychiatry

Disclosure: Nothing to disclose.


Sarah C Langenfeld, MD Assistant Professor, Department of Psychiatry, University of Massachusetts Medical School; Attending Psychiatrist, Community HealthLink

Sarah C Langenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, and Massachusetts Medical Society

Disclosure: Nothing to disclose. Rebecca S Lundquist, MD Consulting Staff, Department of Psychiatry, UMass Memorial Medical Center

Rebecca S Lundquist, MD is a member of the following medical societies: American Psychiatric Association

Disclosure: Pfizer Salary Employment; Biogen Salary Employment

Alan D Schmetzer, MD Professor Emeritus, Interim Chairman, Vice-Chair for Education, Associate Residency Training Director in General Psychiatry, Fellowship Training Director in Addiction Psychiatry, Department of Psychiatry, Indiana University School of Medicine; Addiction Psychiatrist, Midtown Mental Health Cener at Wishard Health Services

Alan D Schmetzer, MD is a member of the following medical societies: American Academy of Addiction Psychiatry, American Academy of Clinical Psychiatrists, American Academy of Psychiatry and the Law, American College of Physician Executives, American Medical Association, American Neuropsychiatric Association, American Psychiatric Association, and Association for Convulsive Therapy

Disclosure: Eli Lilly & Co. Grant/research funds Other

Brian R Szetela, MD Assistant Professor, Department of Psychiatry, University of Massachusetts Medical School; Consulting Psychiatrist, Psychiatric Consultation - Liaison Service, University of Massachusetts Memorial Medical Center

Brian R Szetela, MD is a member of the following medical societies: American Psychiatric Association, American Society of Addiction Medicine, and Association for Convulsive Therapy

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.

  2. Niculescu AB 3rd, Akiskal HS. Proposed endophenotypes of dysthymia: evolutionary, clinical and pharmacogenomic considerations. Mol Psychiatry. 2001 Jul. 6(4):363-6. [Medline].

  3. McCullough JP Jr, Klein DN, Borian FE, Howland RH, Riso LP, Keller MB, et al. Group comparisons of DSM-IV subtypes of chronic depression: validity of the distinctions, part 2. J Abnorm Psychol. 2003 Nov. 112(4):614-22. [Medline].

  4. Kessing LV. Epidemiology of Subtypes of Depression. Acta Psychiatr Scand. 2007. 115 (Suppl 433):85-89.

  5. Murphy JA, Byrne GJ. Prevalence and correlates of the proposed DSM-5 diagnosis of Chronic Depressive Disorder. J Affect Disord. 2012 Feb 29. [Medline].

  6. Olfson M, Liu SM, Grant BF, Blanco C. Influence of comorbid mental disorders on time to seeking treatment for major depressive disorder. Med Care. 2012 Mar. 50(3):227-32. [Medline]. [Full Text].

  7. Keller MB, Harrison W, Fawcett JA, Gelenberg A, Hirschfeld RM, Klein D, et al. Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community. Psychopharmacol Bull. 1995. 31(2):205-12. [Medline].

  8. Klein DN, Schwartz JE, Rose S, Leader JB. Five-year course and outcome of dysthymic disorder: A prospective, naturalistic follow-up study. Am J Psychiatry. 2000 Jun. 157(6):931-9. [Medline].

  9. Klein DN, Shankman SA, Rose S. Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psychiatry. 2006 May. 163(5):872-80. [Medline].

  10. Laptook RS, Klein DN, Dougherty LR. Ten-year stability of depressive personality disorder in depressed outpatients. Am J Psychiatry. 2006 May. 163(5):865-71. [Medline].

  11. Ryder AG, Schuller DR, Bagby RM. Depressive personality and dysthymia: evaluating symptom and syndrome overlap. J Affect Disord. 2006 Apr. 91(2-3):217-27. [Medline].

  12. Markowitz JC, Skodol AE, Petkova E, Xie H, Cheng J, Hellerstein DJ, et al. Longitudinal comparison of depressive personality disorder and dysthymic disorder. Compr Psychiatry. 2005 Jul-Aug. 46(4):239-45. [Medline].

  13. Kelly O, Matheson K, Ravindran A, Merali Z, Anisman H. Ruminative coping among patients with dysthymia before and after pharmacotherapy. Depress Anxiety. 2007. 24(4):233-43. [Medline].

  14. Hermens ML, van Hout HP, Terluin B, van der Windt DA, Beekman AT, et al. The prognosis of minor depression in the general population: a systematic review. Gen Hosp Psychiatry. 2004 Nov-Dec. 26(6):453-62. [Medline].

  15. Johnson JG, Cohen P, Kasen S, Brook JS. Personality disorder traits associated with risk for unipolar depression during middle adulthood. Psychiatry Res. 2005 Sep 15. 136(2-3):113-21. [Medline].

  16. Riolo SA, Nguyen TA, Greden JF, King CA. Prevalence of depression by race/ethnicity: findings from the National Health and Nutrition Examination Survey III. Am J Public Health. 2005 Jun. 95(6):998-1000. [Medline].

  17. Masi G, Millepiedi S, Mucci M, Pascale RR, Perugi G, Akiskal HS. Phenomenology and comorbidity of dysthymic disorder in 100 consecutively referred children and adolescents: beyond DSM-IV. Can J Psychiatry. 2003 Mar. 48(2):99-105. [Medline].

  18. Shankman SA, Klein DN. The impact of comorbid anxiety disorders on the course of dysthymic disorder: a 5-year prospective longitudinal study. J Affect Disord. 2002 Jul. 70(2):211-7. [Medline].

  19. Hayden EP, Klein DN. Outcome of dysthymic disorder at 5-year follow-up: the effect of familial psychopathology, early adversity, personality, comorbidity, and chronic stress. Am J Psychiatry. 2001 Nov. 158(11):1864-70. [Medline].

  20. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov. 163(11):1905-17. [Medline].

  21. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006 Sep. 31(9):1841-53. [Medline].

  22. Adler DA, Irish J, McLaughlin TJ, Perissinotto C, Chang H, Hood M, et al. The work impact of dysthymia in a primary care population. Gen Hosp Psychiatry. 2004 Jul-Aug. 26(4):269-76. [Medline].

  23. Lerner D, Adler DA, Chang H, Lapitsky L, Hood MY, Perissinotto C. Unemployment, job retention, and productivity loss among employees with depression. Psychiatr Serv. 2004 Dec. 55(12):1371-8. [Medline].

  24. Barbui C, Motterlini N, Garattini L. Health status, resource consumption, and costs of dysthymia. A multi-center two-year longitudinal study. J Affect Disord. 2006 Feb. 90(2-3):181-6. [Medline].

  25. Bernal M, Haro JM, Bernert S, Brugha T, de Graaf R, Bruffaerts R, et al. Risk factors for suicidality in Europe: results from the ESEMED study. J Affect Disord. 2007 Aug. 101(1-3):27-34. [Medline].

  26. Bakken K, Vaglum P. Predictors of suicide attempters in substance-dependent patients: a six-year prospective follow-up. Clin Pract Epidemol Ment Health. 2007. 3:20. [Medline].

  27. Casement MD, Shestyuk AY, Best JL, Casas BR, Glezer A, Segundo MA, et al. Anticipation of affect in dysthymia: behavioral and neurophysiological indicators. Biol Psychol. 2008 Feb. 77(2):197-204. [Medline].

  28. Klein DN, Shankman SA, Lewinsohn PM, Rohde P, Seeley JR. Family study of chronic depression in a community sample of young adults. Am J Psychiatry. 2004 Apr. 161(4):646-53. [Medline].

  29. Keitner GI, Ryan CE, Solomon DA. Realistic expectations and a disease management model for depressed patients with persistent symptoms. J Clin Psychiatry. 2006 Sep. 67(9):1412-21. [Medline].

  30. Airaksinen E, Larsson M, Lundberg I, Forsell Y. Cognitive functions in depressive disorders: evidence from a population-based study. Psychol Med. 2004 Jan. 34(1):83-91. [Medline].

  31. Leichsenring F, Hiller W, Weissberg M, Leibing E. Cognitive-behavioral therapy and psychodynamic psychotherapy: techniques, efficacy, and indications. Am J Psychother. 2006. 60(3):233-59. [Medline].

  32. Leichsenring F, Leibing E. Psychodynamic psychotherapy: a systematic review of techniques, indications and empirical evidence. Psychol Psychother. 2007 Jun. 80:217-28. [Medline].

  33. Markowitz JC, Bleiberg KL, Christos P, Levitan E. Solving interpersonal problems correlates with symptom improvement in interpersonal psychotherapy: preliminary findings. J Nerv Ment Dis. 2006 Jan. 194(1):15-20. [Medline].

  34. Markowitz JC, Kocsis JH, Bleiberg KL, Christos PJ, Sacks M. A comparative trial of psychotherapy and pharmacotherapy for "pure" dysthymic patients. J Affect Disord. 2005 Dec. 89(1-3):167-75. [Medline].

  35. Bolton P, Bass J, Neugebauer R, Verdeli H, Clougherty KF, Wickramaratne P. Group interpersonal psychotherapy for depression in rural Uganda: a randomized controlled trial. JAMA. 2003 Jun 18. 289(23):3117-24. [Medline].

  36. Johnson JE, Zlotnick C. A pilot study of group interpersonal psychotherapy for depression in substance-abusing female prisoners. J Subst Abuse Treat. 2008 Jun. 34(4):371-7. [Medline].

  37. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Accessed: May 19, 2009. AHRQ: Agency for Healthcare Research and Quality. Jan. 24, 2007. Available at

  38. Carvalho AF, Cavalcante JL, Castelo MS, Lima MC. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther. 2007 Oct. 32(5):415-28. [Medline].

  39. Lifschytz T, Segman R, Shalom G, Lerer B, Gur E, Golzer T, et al. Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets. 2006 Feb. 7(2):203-10. [Medline].

  40. Tuunainen A, Kripke DF, Endo T. Light therapy for non-seasonal depression. Cochrane Database Syst Rev. 2004. CD004050. [Medline].

  41. Hellerstein DJ, Batchelder S, Miozzo R, Kreditor D, Hyler S, Gangure D. Citalopram in the treatment of dysthymic disorder. Int Clin Psychopharmacol. 2004 May. 19(3):143-8. [Medline].

The various outcomes of dysthymia.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.